Ann Coloproctol.
2021 Jul;37(Suppl 1):S39-S43. 10.3393/ac.2020.00213.0030.
Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report
- Affiliations
-
- 1Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea
- 2Department of Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
- 3Digestive Disease Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea
- 4Department of Radiology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
- 5Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
- KMID: 2518702
- DOI: http://doi.org/10.3393/ac.2020.00213.0030
Abstract
- With the advent of checkpoint inhibitors, it has opened up opportunities for numerous cancer patients. However, as is the case with every treatment, complications need to be weighed. Gastrointestinal adverse effects, such as diarrhea and colitis are well-known complications for checkpoint inhibitors. In severe cases, colitis-induced colonic perforation may occur with an estimation of 1.0% to 1.5% in anti-CTLA-4 antibodies. However, only a handful of cases of such devastating complications have been reported in anti-PD-1 antibodies such as pembrolizumab and nivolumab. We here report a case of intestinal perforation in a patient treated with nivolumab.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Iatrogenic esophageal perforation in a newborn: A case report
- A Case of Esophageal Perforation during Endoscopic Variceal Ligation
- Recurrent Colonic Perforation in Geriatric Patients with Sigmoid Colostomy: Two Case Reports
- A Case of Successful Clipping of a Colonic Perforation during Diagnostic Colonoscopy
- A Case of Esophageal Perforation Cured by Conservative Management after Stent Insertion
